Prospective study of chronic hepatitis C treated with reduced initial ribavirin dose

Hepato-Gastroenterology

Volumn 57, Issue 102-103, 2010, Pages 1227-1231

  Konishi, Ichiro ^a   Hiasa, Yoichi ^a   Nonaka, Takashi ^b   Hiraoka, Atsushi ^c   Joko, Kouji ^d   Tokumoto, Yoshio ^a   Abe, Masanori ^a   Matsuura, Bunzo ^a   Michitaka, Kojiro ^c   Horiike, Norio ^e   Onji, Morikazu ^a  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Ehime Prefecture Niihama Hospital   (Japan)

^c EHIME PREFECTURAL CENTRAL HOSPITAL   (Japan)

^d MATSUYAMA RED CROSS HOSPITAL   (Japan)

^e Department of Internal Medicine   (Japan)

Author keywords

Anemia; Clinical trial; Hepatitis C; Peginterferon alfa 2b; Ribavirin

Indexed keywords

HEMOGLOBIN; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; DEPRESSION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEROTYPE; TREATMENT RESPONSE;

AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBINS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RIBAVIRIN; RNA, VIRAL;

EID: 79251563450     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Fried MW, Shiftman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
2. Shiffman ML, Di Bisceglie AM, Lindsay KL, Morishima C, Wright EC, Everson GT, et al: Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004; 126:1015-1023.
3. Hadziyannis SJ, Sette H, Jr., Morgan TR, Balan V, Diago M, Marcellin P, et al: Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140:346-355.
4. McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, et al: Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123:1061-1069.
5. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J: Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38:645-652. (Pubitemid 37052151)
6. Dan AA, Martin LM, Crone C, Ong JP, Farmer DW, Wise T, et al: Depression, anemia and health-related quality of life in chronic hepatitis C. J Hepatol 2006; 44:491-498.
7. Fried MW: Side effects of therapy of hepatitis C and their management. Hepatology 2002; 36:S237-244.
8. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ: Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology (Baltimore, Md 1994; 19:1513-1520.
9. Hornfeldt E, Gjertsen H, Weiland O: High adherence with a low initial ribavirin dose in combination with pegylated-IFN alpha-2a for treatment of recurrent hepatitis C after liver transplantation. Scand J Infect Dis 2008; 40:259-265.
10. Shiffman ML, Ghany MG, Morgan TR, Wright EC, Everson GT, Lindsay KL, et al: Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology 2007; 132:103-112.
11. Pearlman BL, Ehleben C, Saifee S: Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders. Hepatology 2007; 46:1688-1694.
12. Fujiwara K, Kaneko S, Kakumu S, Sata M, Hige S, Tomita E, et al: Double filtration plasmapheresis and interferon combination therapy for chronic hepatitis C patients with genotype 1 and high viral load. Hepatol Res 2007; 37:701-710.
13. Talal AH, Weisz K, Hau T, Kreiswirth S, Dieterich DT: A preliminary study of erythropoietin for anemia associated with ribavirin and interferon-alpha. Am J Gastroenterol 2001; 96:2802-2804.
14. Dieterich DT, Wasserman R, Brau N, Hassanein TI, Bini EJ, Bowers PJ, et al: Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. Am J Gastroenterol 2003; 98:2491-2499.
15. Hezode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, et al: Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360:1839-1850.